Dr. Eugenia Chang
Claim this profileSaint Luke's Cancer Institute - Boise
Expert in Uterine Tumors
Expert in Cerebral Gliomas
52 reported clinical trials
97 drugs studied
About Eugenia Chang
Education:
- Earned a Medical degree (MD) from an accredited medical school.
- Completed Residency in Radiation Oncology at Saint Luke's Cancer Institute - Boise.
- Board certified in Radiation Oncology.
Experience:
- Currently serving as a Radiation Oncologist at Saint Luke's Cancer Institute - Boise.
Area of expertise
1Uterine Tumors
Global LeaderStage IV
NTRK1 positive
NTRK positive
2Cerebral Gliomas
Global LeaderStage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Eugenia Chang is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Eugenia Chang
Clinical Trial Related7 years of experience running clinical trials · Led 52 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Eugenia Chang has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Vincristine Sulfate
- Doxorubicin Hydrochloride
- Laboratory Biomarker Analysis
Breakdown of trials Eugenia Chang has run
Uterine Tumors
Cerebral Gliomas
Cancer
Neuroblastoma
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Eugenia Chang specialize in?
Is Eugenia Chang currently recruiting for clinical trials?
Are there any treatments that Eugenia Chang has studied deeply?
What is the best way to schedule an appointment with Eugenia Chang?
What is the office address of Eugenia Chang?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.